Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals, Inc. (AMLX)
:AMLX
AMLX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.00 - $8.72
Previous CloseN/A
Volume98.90K
Average Volume (3M)1.38M
Market Cap
$731.17M
Enterprise Value$396.51M
Total Cash (Recent Filing)$204.07M
Total Debt (Recent Filing)$1.38M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Nov 06, 2025EPS Estimate
-0.46Last Dividend Ex-Date
Mar 28, 2018Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding89,167,435
10 Day Avg. Volume1,017,186
30 Day Avg. Volume1,382,924
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.54
Enterprise Value/Revenue-311.73
Enterprise Value/Gross Profit-40.19
Enterprise Value/Ebitda-2.32
Forecast
1Y Price Target
$11.38Price Target Upside38.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company presented positive 48-week long-term data from the Phase 2 HELIOS trial, showing sustained improvement in key health metrics.
Financial PerformanceThe company ended the quarter with approximately $180M of cash, providing cash runway through the end of 2026.
Market OpportunityThe medically important PBH population could exceed the commonly cited 167,000 patients, indicating a larger market opportunity for avexitide.
Bears Say
AwarenessThere might be work needed in terms of awareness, especially among primary care physicians, with respect to early diagnosis and establishment of an official PBH code.
CompetitionDespite the rise of GLP-1 receptor agonists, Roux-en-Y gastric bypass remains indispensable, indicating a sustained need for alternative treatments like avexitide.
Market AwarenessAbsence of ICD-10 coding and severe underdiagnosis undermines the true prevalence of the disease.
Amylyx Pharmaceuticals Inc News
AMLX FAQ
What was Amylyx Pharmaceuticals, Inc.’s price range in the past 12 months?
Amylyx Pharmaceuticals, Inc. lowest stock price was $2.00 and its highest was $8.72 in the past 12 months.
What is Amylyx Pharmaceuticals, Inc.’s market cap?
Amylyx Pharmaceuticals, Inc.’s market cap is $731.17M.
When is Amylyx Pharmaceuticals, Inc.’s upcoming earnings report date?
Amylyx Pharmaceuticals, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 84 days.
How were Amylyx Pharmaceuticals, Inc.’s earnings last quarter?
Amylyx Pharmaceuticals, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.444 by -$0.016.
Is Amylyx Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Amylyx Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Amylyx Pharmaceuticals, Inc. pay dividends?
Amylyx Pharmaceuticals, Inc. pays a Quarterly dividend of $0.42 which represents an annual dividend yield of N/A. See more information on Amylyx Pharmaceuticals, Inc. dividends here
What is Amylyx Pharmaceuticals, Inc.’s EPS estimate?
Amylyx Pharmaceuticals, Inc.’s EPS estimate is -0.46.
How many shares outstanding does Amylyx Pharmaceuticals, Inc. have?
Amylyx Pharmaceuticals, Inc. has 89,167,435 shares outstanding.
What happened to Amylyx Pharmaceuticals, Inc.’s price movement after its last earnings report?
Amylyx Pharmaceuticals, Inc. reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.444. Following the earnings report the stock price went down -4.274%.
Which hedge fund is a major shareholder of Amylyx Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in AMLX
Amylyx Pharmaceuticals Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.38 (38.78% Upside)
$11.38 (38.78% Upside)
Blogger Sentiment
Bullish
AMLX Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.5%
Last 30 Days ▲ 9.8%
Last 30 Days ▲ 9.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
314.14%
12-Months-Change
Fundamentals
Return on Equity
-87.42%
Trailing 12-Months
Asset Growth
-41.41%
Trailing 12-Months
Company Description
Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
AMLX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call emphasizes significant progress in clinical trials for Avexitide and AMX0035, alongside financial stability with reduced expenses. However, challenges remain in cash management and market education. Overall, the highlights in drug development and financial management outweigh the concerns, indicating a positive outlook.View all AMLX earnings summariesAMLX Stock 12 Month Forecast
Average Price Target
$11.38
▲(38.78% Upside)
Technical Analysis
Benitec Biopharma
―
Checkpoint Therapeutics
―
Allogene Therapeutics
―
Eton Pharmaceuticals
―
Zenas BioPharma, Inc.
―
Ownership Overview
9.33% Insiders
6.96% Mutual Funds
0.02% Other Institutional Investors
72.88% Public Companies and
Individual Investors